However, the feasibility of using it to treat metabolic disorders and neurodegenerative diseases is currently under investigation in clinical trials (Liu Y
299 Considering the profound impact of the gut microbiota on the immune system, research investigating the modulation of the gut microbiota via dietary interventions to optimize cancer treatment efficacy has been predominantly centered around immunotherapy
[3][4] Retatrutide is a next-generation triple agonist designed to simultaneously activate GLP-1, GIP, and glucagon receptors
Orforglipron does not require fasting or other dosing restrictions, which may offer a meaningful practical advantage for patients
Those three statements do not agree, so the label and instructions supplied with the actual prescription are the authority here
Patients experiencing greater than 1.5% body weight loss per week face elevated risk